The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

1. Identifying information.

2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.


This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

5. Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

**Other:** Anything not covered under the previous three boxes

**Pending:** The patent has been filed but not issued

**Issued:** The patent has been issued by the agency

**Licensed:** The patent has been licensed to an entity, whether earning royalties or not

**Royalties:** Funds are coming in to you or your institution due to your patent
ICMJE Form for Disclosure of Potential Conflicts of Interest

Section 1. Identifying Information

1. Given Name (First Name)  
Amon  

2. Surname (Last Name)  
Asgharpour  

3. Date  
20-April-2020  

4. Are you the corresponding author?  
☐ Yes  ☑ No  
Corresponding Author’s Name  
Scott Friedman  

5. Manuscript Title  
Basic Science to Clinical Trials in NAFLD and ALD: Collaboration with Industry  

6. Manuscript Identifying Number (if you know it)  

Section 2. The Work Under Consideration for Publication

Did you or your institution at any time receive payment or services from a third party (government, commercial, private foundation, etc.) for any aspect of the submitted work (including but not limited to grants, data monitoring board, study design, manuscript preparation, statistical analysis, etc.)?  

Are there any relevant conflicts of interest?  
☐ Yes  ☑ No  

Section 3. Relevant financial activities outside the submitted work.

Place a check in the appropriate boxes in the table to indicate whether you have financial relationships (regardless of amount of compensation) with entities as described in the instructions. Use one line for each entity; add as many lines as you need by clicking the “Add +” box. You should report relationships that were present during the 36 months prior to publication.  

Are there any relevant conflicts of interest?  
☑ Yes  ☐ No  

If yes, please fill out the appropriate information below.

<table>
<thead>
<tr>
<th>Name of Entity</th>
<th>Grant?</th>
<th>Personal Fees?</th>
<th>Non-Financial Support?</th>
<th>Other?</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Intercept Pharmaceutical</td>
<td>☐</td>
<td>☑</td>
<td></td>
<td>☐</td>
<td></td>
</tr>
<tr>
<td>Gilead Sciences</td>
<td>☐</td>
<td>☑</td>
<td></td>
<td>☐</td>
<td></td>
</tr>
<tr>
<td>Genfit</td>
<td>☐</td>
<td>☑</td>
<td></td>
<td>☐</td>
<td></td>
</tr>
<tr>
<td>Expert Connect</td>
<td>☐</td>
<td>☑</td>
<td></td>
<td>☐</td>
<td></td>
</tr>
<tr>
<td>NASHNET</td>
<td>☐</td>
<td>☑</td>
<td></td>
<td>☐</td>
<td></td>
</tr>
<tr>
<td>SanyalBio</td>
<td>☐</td>
<td>☑</td>
<td></td>
<td>☐</td>
<td></td>
</tr>
<tr>
<td>MEDACorp</td>
<td>☐</td>
<td>☑</td>
<td></td>
<td>☐</td>
<td></td>
</tr>
<tr>
<td>Sterotherapeutics</td>
<td>☐</td>
<td>☑</td>
<td></td>
<td>☐</td>
<td></td>
</tr>
</tbody>
</table>
ICMJE Form for Disclosure of Potential Conflicts of Interest

Section 4. Intellectual Property -- Patents & Copyrights

Do you have any patents, whether planned, pending or issued, broadly relevant to the work?  ☐ Yes  ☑ No

Section 5. Relationships not covered above

Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?

☐ Yes, the following relationships/conditions/circumstances are present (explain below):

☑ No other relationships/conditions/circumstances that present a potential conflict of interest

At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships.

Section 6. Disclosure Statement

Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.

Dr. Asgharpour reports personal fees from Intercept Pharmaceutical, personal fees from Gilead Sciences, personal fees from Genfit, personal fees from Expert Connect, personal fees from NASHNET, personal fees from SanyalBio, personal fees from MEDACorp, personal fees from Sterotherapeutics, outside the submitted work.

Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.
ICMJE Form for Disclosure of Potential Conflicts of Interest

Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

1. Identifying information.

2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.


This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

5. Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

**Other:** Anything not covered under the previous three boxes

**Pending:** The patent has been filed but not issued

**Issued:** The patent has been issued by the agency

**Licensed:** The patent has been licensed to an entity, whether earning royalties or not

**Royalties:** Funds are coming in to you or your institution due to your patent
ICMJE Form for Disclosure of Potential Conflicts of Interest

**Section 1. Identifying Information**

1. Given Name (First Name)  
   Amreen

2. Surname (Last Name)  
   Dinani

3. Date  
   21-April-2020

4. Are you the corresponding author?  
   ✔ No

5. Manuscript Title  
   Basic Science to Clinical Trials in NAFLD & ALD: Collaboration with Industry

6. Manuscript Identifying Number (if you know it)  
   TGH-2019-NAFLD-12(TGH-19-224)

**Section 2. The Work Under Consideration for Publication**

Did you or your institution at any time receive payment or services from a third party (government, commercial, private foundation, etc.) for any aspect of the submitted work (including but not limited to grants, data monitoring board, study design, manuscript preparation, statistical analysis, etc.)?  

Are there any relevant conflicts of interest?  
   ✔ No

**Section 3. Relevant financial activities outside the submitted work.**

Place a check in the appropriate boxes in the table to indicate whether you have financial relationships (regardless of amount of compensation) with entities as described in the instructions. Use one line for each entity; add as many lines as you need by clicking the “Add +” box. You should report relationships that were present during the 36 months prior to publication.

Are there any relevant conflicts of interest?  
   ✔ Yes  
   ✔ No

If yes, please fill out the appropriate information below.

<table>
<thead>
<tr>
<th>Name of Entity</th>
<th>Grant?</th>
<th>Personal Fees?</th>
<th>Non-Financial Support?</th>
<th>Other?</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Genfit</td>
<td>☑</td>
<td>☑</td>
<td></td>
<td></td>
<td>Consulting, Lectures</td>
</tr>
<tr>
<td>Intercept</td>
<td>☑</td>
<td></td>
<td></td>
<td></td>
<td>Consulting, Speakers Bureau</td>
</tr>
<tr>
<td>Gilead Sciences</td>
<td>☑</td>
<td></td>
<td></td>
<td></td>
<td>Consulting, Advisory Board</td>
</tr>
<tr>
<td>Expert Connect</td>
<td>☑</td>
<td></td>
<td></td>
<td></td>
<td>Consulting</td>
</tr>
<tr>
<td>NASHNET</td>
<td>☑</td>
<td></td>
<td></td>
<td></td>
<td>Consulting, Honoraria</td>
</tr>
</tbody>
</table>
Section 4. Intellectual Property -- Patents & Copyrights

Do you have any patents, whether planned, pending or issued, broadly relevant to the work? ☐ Yes  ✔ No

Section 5. Relationships not covered above

Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?

☐ Yes, the following relationships/conditions/circumstances are present (explain below):

✔ No other relationships/conditions/circumstances that present a potential conflict of interest

At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships.

Section 6. Disclosure Statement

Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.

Dr. Dinani reports personal fees from Genfit, personal fees from Intercept, personal fees from Gilead Sciences, personal fees from Expert Connect, personal fees from NASHNET, outside the submitted work.

Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.
ICMJE Form for Disclosure of Potential Conflicts of Interest

Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

1. Identifying information.

2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking “No” means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check “Yes”.

3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.


This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

5. Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

- **Entity**: government agency, foundation, commercial sponsor, academic institution, etc.
- **Grant**: A grant from an entity, generally [but not always] paid to your organization
- **Personal Fees**: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations
- **Non-Financial Support**: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.
- **Other**: Anything not covered under the previous three boxes
- **Pending**: The patent has been filed but not issued
- **Issued**: The patent has been issued by the agency
- **Licensed**: The patent has been licensed to an entity, whether earning royalties or not
- **Royalties**: Funds are coming in to you or your institution due to your patent
Section 1. Identifying Information

1. Given Name (First Name)  
Scott

2. Surname (Last Name)  
Friedman

3. Date  
21-April-2020

4. Are you the corresponding author?  
☑ Yes   ☐ No

5. Manuscript Title  
Basic Science to Clinical Trials in NAFLD & ALD: Collaboration with Industry

6. Manuscript Identifying Number (if you know it)  
TGH-2019-NAFLD-12(TGH-19-224)

Section 2. The Work Under Consideration for Publication

Did you or your institution at any time receive payment or services from a third party (government, commercial, private foundation, etc.) for any aspect of the submitted work (including but not limited to grants, data monitoring board, study design, manuscript preparation, statistical analysis, etc.)?  
Are there any relevant conflicts of interest?  
☑ Yes   ☐ No

Section 3. Relevant financial activities outside the submitted work.

Place a check in the appropriate boxes in the table to indicate whether you have financial relationships (regardless of amount of compensation) with entities as described in the instructions. Use one line for each entity; add as many lines as you need by clicking the “Add +” box. You should report relationships that were present during the 36 months prior to publication.  
Are there any relevant conflicts of interest?  
☑ Yes   ☐ No
If yes, please fill out the appropriate information below.

<table>
<thead>
<tr>
<th>Name of Entity</th>
<th>Grant?</th>
<th>Personal Fees?</th>
<th>Non-Financial Support?</th>
<th>Other?</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>89 Bio</td>
<td></td>
<td>✓</td>
<td></td>
<td></td>
<td>Consulting</td>
</tr>
<tr>
<td>Axcella Health</td>
<td></td>
<td>✓</td>
<td></td>
<td></td>
<td>Consulting</td>
</tr>
<tr>
<td>Blade Therapeutics</td>
<td></td>
<td>✓</td>
<td></td>
<td></td>
<td>Consulting</td>
</tr>
<tr>
<td>Bristol Myers Squibb</td>
<td></td>
<td>✓</td>
<td></td>
<td></td>
<td>Consulting</td>
</tr>
<tr>
<td>Can-Fite Biopharma</td>
<td></td>
<td>✓</td>
<td></td>
<td></td>
<td>Consulting</td>
</tr>
<tr>
<td>ChemomAb</td>
<td></td>
<td>✓</td>
<td></td>
<td></td>
<td>Consulting</td>
</tr>
<tr>
<td>Escient Therapeutics</td>
<td></td>
<td>✓</td>
<td></td>
<td></td>
<td>Consulting</td>
</tr>
<tr>
<td>Forbion</td>
<td></td>
<td>✓</td>
<td></td>
<td></td>
<td>Consulting</td>
</tr>
</tbody>
</table>
ICMJE Form for Disclosure of Potential Conflicts of Interest

<table>
<thead>
<tr>
<th>Name of Entity</th>
<th>Grant?</th>
<th>Personal Fees?</th>
<th>Non-Financial Support?</th>
<th>Other?</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Galmed</td>
<td>✔</td>
<td>✔</td>
<td></td>
<td>✔</td>
<td>Consulting, Stock &lt; 1%</td>
</tr>
<tr>
<td>Genevant</td>
<td></td>
<td>✔</td>
<td></td>
<td></td>
<td>Consulting</td>
</tr>
<tr>
<td>Genfit</td>
<td></td>
<td>✔</td>
<td></td>
<td></td>
<td>Consulting, Stock &lt; 1%</td>
</tr>
<tr>
<td>Gordian Biotechnology</td>
<td></td>
<td>✔</td>
<td></td>
<td></td>
<td>Consulting</td>
</tr>
<tr>
<td>Glympse Bio</td>
<td></td>
<td>✔</td>
<td></td>
<td></td>
<td>Consulting</td>
</tr>
<tr>
<td>Glycotest</td>
<td></td>
<td>✔</td>
<td></td>
<td></td>
<td>Consulting</td>
</tr>
<tr>
<td>Indalo Therapeutics</td>
<td></td>
<td>✔</td>
<td></td>
<td>✔</td>
<td>Consulting, Stock &lt; 1%</td>
</tr>
<tr>
<td>Metacrine Inc.</td>
<td></td>
<td>✔</td>
<td></td>
<td>✔</td>
<td>Consulting, Stock &lt; 1%</td>
</tr>
<tr>
<td>Morphic Therapeutics</td>
<td>✔</td>
<td>✔</td>
<td></td>
<td></td>
<td>Consulting</td>
</tr>
<tr>
<td>North Sea Therapeutics</td>
<td></td>
<td>✔</td>
<td></td>
<td>✔</td>
<td>Consulting, Stock &lt; 1%</td>
</tr>
<tr>
<td>Novartis</td>
<td></td>
<td>✔</td>
<td></td>
<td></td>
<td>Consulting</td>
</tr>
<tr>
<td>Novo Nordisk</td>
<td></td>
<td>✔</td>
<td></td>
<td></td>
<td>Consulting</td>
</tr>
<tr>
<td>Ono Pharmaceuticals</td>
<td></td>
<td>✔</td>
<td></td>
<td></td>
<td>Consulting</td>
</tr>
<tr>
<td>Pfizer Pharmaceuticals</td>
<td></td>
<td>✔</td>
<td></td>
<td></td>
<td>Consulting</td>
</tr>
<tr>
<td>Scholar Rock</td>
<td></td>
<td>✔</td>
<td></td>
<td>✔</td>
<td>Consulting, Stock &lt; 1%</td>
</tr>
<tr>
<td>Surrozen</td>
<td></td>
<td>✔</td>
<td></td>
<td>✔</td>
<td>Consulting, Stock &lt; 1%</td>
</tr>
<tr>
<td>Viking Therapeutics</td>
<td></td>
<td>✔</td>
<td></td>
<td></td>
<td>Consulting</td>
</tr>
<tr>
<td>Akarna Therapeutics</td>
<td></td>
<td></td>
<td></td>
<td>✔</td>
<td>Stock &lt; 1%</td>
</tr>
<tr>
<td>BirdRock Bio</td>
<td></td>
<td></td>
<td></td>
<td>✔</td>
<td>Stock &lt; 1%</td>
</tr>
<tr>
<td>Blade Therapeutics</td>
<td></td>
<td></td>
<td></td>
<td>✔</td>
<td>Stock &lt; 1%</td>
</tr>
<tr>
<td>Conatus</td>
<td></td>
<td></td>
<td></td>
<td>✔</td>
<td>Stock &lt; 1%</td>
</tr>
<tr>
<td>DeuteRx</td>
<td></td>
<td></td>
<td></td>
<td>✔</td>
<td>Stock &lt; 1%</td>
</tr>
<tr>
<td>Escent</td>
<td></td>
<td></td>
<td></td>
<td>✔</td>
<td>Stock &lt; 1%</td>
</tr>
<tr>
<td>Exalenz</td>
<td></td>
<td></td>
<td></td>
<td>✔</td>
<td>Stock &lt; 1%</td>
</tr>
<tr>
<td>Galectin</td>
<td></td>
<td></td>
<td></td>
<td>✔</td>
<td>Stock &lt; 1%</td>
</tr>
<tr>
<td>Glympse</td>
<td></td>
<td></td>
<td></td>
<td>✔</td>
<td>Stock &lt; 1%</td>
</tr>
<tr>
<td>Intercept</td>
<td></td>
<td></td>
<td></td>
<td>✔</td>
<td>Stock &lt;1%</td>
</tr>
<tr>
<td>Lifemax</td>
<td></td>
<td></td>
<td></td>
<td>✔</td>
<td>Stock &lt; 1%</td>
</tr>
<tr>
<td>Nimbus</td>
<td></td>
<td></td>
<td></td>
<td>✔</td>
<td>Stock &lt; 1%</td>
</tr>
<tr>
<td>Madrigal</td>
<td></td>
<td></td>
<td></td>
<td>✔</td>
<td>Stock &lt;1%</td>
</tr>
</tbody>
</table>
Section 4. Intellectual Property -- Patents & Copyrights

Do you have any patents, whether planned, pending or issued, broadly relevant to the work?  
☐ Yes  ✔ No

Section 5. Relationships not covered above

Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?

☐ Yes, the following relationships/conditions/circumstances are present (explain below):

✔ No other relationships/conditions/circumstances that present a potential conflict of interest

At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships.

Section 6. Disclosure Statement

Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.

Dr. Friedman reports personal fees from 89 Bio, personal fees from Axcella Health, personal fees from Blade Therapeutics, personal fees from Bristol Myers Squibb, personal fees from Can-Fite Biopharma, personal fees from ChemomAb, personal fees from Esient Therapeutics, personal fees from Forbion, grants, personal fees and other from Galmed, personal fees from Genevant, personal fees and other from Genfit, personal fees from Gordian Biotechnology, personal fees from Glympse Bio, personal fees from Glycotest, personal fees and other from Indalo Therapeutics, personal fees and other from Metacrine Inc., grants and personal fees from Morphic Therapeutics, personal fees and other from North Sea Therapeutics, personal fees from Novartis, personal fees from Novo Nordisk, personal fees from Ono Pharmaceuticals, personal fees from Pfizer Pharmaceuticals, personal fees and other from Scholar Rock, personal fees and other from Surrozen, personal fees from Viking Therapeutics, other from Akarna Therapeutics, other from BirdRock Bio, other from Blade Therapeutics, other from Conatus, other from DeuteRx, other from Esient, other from Exalenz, other from Galectin, other from Glympse, other from Intercept, other from Lifemax, other from Nimbus, other from Madrigal, outside the submitted work.

Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.